Literature DB >> 621628

Plasma concentrations of thioridazine metabolites and ECG abnormalities.

L A Gottschalk, E Dinovo, R Biener, B R Nandi.   

Abstract

Five acute schizophrenic patients were given a standard thioridazine dose (4 mg/kg/day po). Their plasma concentrations of thioridazine and its metabolites were determined by GLC, and their ECG's were recorded routinely. In four of the five patients, abnormal ECG's (malformation of the T-wave or lengthening of the repolarization time) were found whenever plasma concentrations of the thioridazine ring sulfoxide were elevated. No relationship could be detected between the appearance of ECG abnormalities and the concentrations of thioridazine and its other metabolites.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 621628     DOI: 10.1002/jps.2600670208

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

1.  Effects of licence change on prescribing and poisons enquiries for antipsychotic agents in England and Scotland.

Authors:  D N Bateman; A M Good; R Afshari; C A Kelly
Journal:  Br J Clin Pharmacol       Date:  2003-06       Impact factor: 4.335

2.  Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants.

Authors:  W A Daniel; M Syrek; A Haduch; J Wójcikowski
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

3.  A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia.

Authors:  Lili Aslostovar; Allison L Boyd; Mohammed Almakadi; Tony J Collins; Darryl P Leong; Rommel G Tirona; Richard B Kim; Jim A Julian; Anargyros Xenocostas; Brian Leber; Mark N Levine; Ronan Foley; Mickie Bhatia
Journal:  Blood Adv       Date:  2018-08-14

4.  Structural changes by sulfoxidation of phenothiazine drugs.

Authors:  S G Dahl; P A Kollman; S N Rao; U C Singh
Journal:  J Comput Aided Mol Des       Date:  1992-06       Impact factor: 3.686

5.  The disposition and elimination of stereoisomeric pairs of thioridazine 5-sulfoxide in the rat.

Authors:  P W Hale; S Melethil; A Poklis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Oct-Dec       Impact factor: 2.441

6.  The biotransformation of thioridazine to thioridazine 5-sulfoxide stereoisomers in phenobarbital induced rats.

Authors:  P W Hale; A Poklis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Oct-Dec       Impact factor: 2.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.